All In MedTech

Device Trial Radar · NCT07286890

Getinge's Beating Heart Product Family Post-Market Clinical Follow-up (PMCF) Study

A Real-World Post-Market Clinical Follow-Up Study to Evaluate the Safety and Performance of Getinge's Beating Heart Product Family in Patients Undergoing Beating Heart Coronary Artery Bypass Graft Surgery

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Maquet CardiovascularNot on our public-company list
Sponsor type
Industry
First posted
Dec 16, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational study aims to collect data on the performance and safety of Getinge's Beating Heart products used during open-heart coronary artery bypass graft surgery. The surgery and the use of the study devices will be done according to the standard of care. Participants will not be required to undergo any study-specific procedures, and information will be collected only until hospital discharge following the surgery.

Conditions

  • Off Pump Coronary Artery Bypass Surgery

Interventions

  • Vacuum Stabilizer SystemDevice

    Isolates and provides local immobilization of the target vessel while performing the distal anastomosis on a beating heart.

  • Vacuum Positioner SystemDevice

    Positions the heart and exposes the coronary artery(ies) when performing the distal anastomosis on a beating heart.

  • Blower/MisterDevice

    Reduces blood in the operative field to improve visibility while performing an anastomosis on a beating heart.

  • Proximal Seal SystemDevice

    Proximal anastomotic seal technology allows for clampless hemostasis during proximal anastomosis when performing Coronary Artery Bypass Graft (CABG) procedures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of device-related adverse eventsTime frame: Time period from procedure through study completion, an average of 7 days
  2. Incidence of device-related serious adverse eventsTime frame: Time period from procedure through study completion, an average of 7 days
  3. Incidence of technical successTime frame: Perioperative/Periprocedural

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • St. Joseph's Medical Center Stockton

    Stockton, California · Recruiting

  • Aspirus Medical Group

    Wausau, Wisconsin · Recruiting

  • University Medical Center Rostock

    Rostock, Germany · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.